2 recruiting, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Completed 1 |
Follow NSCLC Stage IV: new trials by email Literature Review of NSCLC Stage IV trials Research Report on NSCLC Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy N-803, Tislelizumab, Docetaxel - NSCLC Stage IV | Phase 3 | Recruiting | ImmunityBio, Inc. | 507 | 2025-10-01 | 2026-11-02 |
| Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer Stereotactic Body Radiotherapy, second-line systemic therapy - Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 104 | 2024-09-01 | 2024-08-30 |
| MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC Bevacizumab as MYL-1402O, Bevacizumab as Avastin - NSCLC Stage IV | Phase 3 | Completed | Mylan Pharmaceuticals Inc | 671 | 2017-01-21 | 2022-03-16 |
Carcinoma, Non-Small-Cell Lung (3)
Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3)
ALT-803 (1) · Bevacizumab (1) · Docetaxel (1) · Immunotherapy (1) · Radiosurgery (1) · tislelizumab (1)
ImmunityBio, Inc. (1) · Mylan Pharmaceuticals Inc (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
Belarus (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Canada (1) · China (1) · Croatia (1) · Georgia (1) · Hungary (1) · India (1) · Italy (1) · Philippines (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1)
Fuming Qiu, PhD (1) · Tazeen A Idris, MD (1)